Reblozyl (luspatercept-aamt)

Adult Dosing .

Dosage forms:  INJ

Special Note

[drug name clarification]

Info: nonproprietary name = luspatercept-aamt

anemia

[beta thalassemia-associated]

Dose: 1-1.25 mg/kg/dose SC q3wk; Start: 1 mg/kg/dose SC q3wk for at least 6wk, incr. to 1.25 mg/kg/dose SC q3wk if no reduction in RBC transfusion burden; Max: 1.25 mg/kg/dose; Info: for patients requiring regular RBC transfusion; if pre-dose Hgb 11.5 g/dL or greater in absence of recent transfusion, hold tx until Hgb <11 g/dL, then restart at same dose; see pkg insert for dose adjustments based on toxicities or if Hgb incr. >2 g/dL within 3wk of dose in absence of transfusion; D/C if no decr. in RBC transfusion burden after 9wk at max dose

[myelodysplastic syndrome-associated, ESA-naive]

Dose: 1-1.75 mg/kg/dose SC q3wk; Start: 1 mg/kg/dose SC q3wk for at least 6wk, incr. to 1.33 mg/kg/dose SC q3wk if no transfusion independence or Hgb <10 g/dL with incr. <1 g/dL since last dose; after at least 6wk at 1.33 mg/kg/dose, incr. to 1.75 mg/kg/dose SC q3wk if no transfusion independence or Hgb <10 g/dL with incr. <1 g/dL since last dose; Max: 1.75 mg/kg/dose; Info: for patients with very low-intermediate risk disease who may require RBC transfusion; if pre-dose Hgb 12 g/dL or greater in absence of recent transfusion, hold tx until Hgb <11 g/dL, then restart at same dose; see pkg insert for dose adjustments based on toxicities or if Hgb incr. >2 g/dL within 3wk of dose in absence of transfusion; D/C if no decr. in RBC transfusion burden after 9wk at max dose

[myelodysplastic syndrome with ring sideroblasts (MDS-RS)-associated, ESA-refractory or intolerant]

Dose: 1-1.75 mg/kg/dose SC q3wk; Start: 1 mg/kg/dose SC q3wk for at least 6wk, incr. to 1.33 mg/kg/dose SC q3wk if no transfusion independence; after at least 6wk at 1.33 mg/kg/dose, incr. to 1.75 mg/kg/dose SC q3wk if no transfusion independence; Max: 1.75 mg/kg/dose; Info: for patients with very low-intermediate risk disease requiring 2 or more RBC units over 8wk; if pre-dose Hgb 11.5 g/dL or greater in absence of recent transfusion, hold tx until Hgb <11 g/dL, then restart at same dose; see pkg insert for dose adjustments based on toxicities or if Hgb incr. >2 g/dL within 3wk of dose in absence of transfusion; D/C if no decr. in RBC transfusion burden after 9wk at max dose

[myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)-associated, ESA-refractory or intolerant]

Dose: 1-1.75 mg/kg/dose SC q3wk; Start: 1 mg/kg/dose SC q3wk for at least 6wk, incr. to 1.33 mg/kg/dose SC q3wk if no transfusion independence; after at least 6wk at 1.33 mg/kg/dose, incr. to 1.75 mg/kg/dose SC q3wk if no transfusion independence; Max: 1.75 mg/kg/dose; Info: for patients with very low-intermediate risk disease requiring 2 or more RBC units over 8wk; if pre-dose Hgb 11.5 g/dL or greater in absence of recent transfusion, hold tx until Hgb <11 g/dL, then restart at same dose; see pkg insert for dose adjustments based on toxicities or if Hgb incr. >2 g/dL within 3wk of dose in absence of transfusion; D/C if no decr. in RBC transfusion burden after 9wk at max dose

renal dosing

[see below]

CrCl >30: no adjustment; CrCl <30: not defined

HD/PD: not defined

hepatic dosing

[see below]

AST/ALT >1-3x ULN: no adjustment; AST/ALT >3x ULN: not defined

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.